Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology (Nasdaq: KURA) announced that on November 3, 2025 its Compensation Committee granted inducement nonstatutory stock options to a new non-executive employee under the company's 2023 Inducement Option Plan, as amended.
The grant totals 21,750 options with an exercise price of $9.77 per share (the closing price on November 3, 2025). Options vest over four years: 25% at one year then monthly over the following 36 months, subject to continued service, and are governed by the plan and a stock option agreement. The committee approved the award as an inducement in accordance with Nasdaq Listing Rule 5635(c)(4).
Kura Oncology (Nasdaq: KURA) ha annunciato che il 3 novembre 2025 il suo Compensation Committee ha concesso stock options non statutarie di inducement a un nuovo dipendente non dirigente ai sensi del piano 2023 Inducement Option Plan, come modificato.
L'assegnazione ammonta a 21.750 opzioni con un prezzo di esercizio di 9,77$ per azione (il prezzo di chiusura del 3 novembre 2025). Le opzioni maturano nel corso di quattro anni: 25% dopo un anno, poi mensilmente nei successivi 36 mesi, soggette a continuato servizio, e sono regolamentate dal piano e da un accordo di stock option. Il comitato ha approvato l'assegnazione come inducement in conformità con Nasdaq Listing Rule 5635(c)(4).
Kura Oncology (Nasdaq: KURA) anunció que el 3 de noviembre de 2025 su Comité de Compensación otorgó opciones de acciones no estatutarias por incentivo a un nuevo empleado no directivo bajo el plan de Opciones de Inducción de 2023, según enmendado.
La asignación totaliza 21,750 opciones con un precio de ejercicio de $9.77 por acción (el precio de cierre del 3 de noviembre de 2025). Las opciones se consolidan en cuatro años: 25% al cabo de un año, luego mensualmente durante los 36 meses siguientes, sujeto a continuo servicio, y se rigen por el plan y por un acuerdo de opciones sobre acciones. El comité aprobó la adjudicación como inducción de conformidad con la Regla 5635(c)(4) de Nasdaq Listing.
Kura Oncology (나스닥: KURA)는 2025년 11월 3일에 보상위원회가 새로운 비상근 직원에게 회사의 2023 Inducement Option Plan(개선 시 개정)에 따라 유도성 비상장 주식매수선택권을 부여했다고 발표했습니다.
이번 부여는 총 21,750주의 옵션이며 행사가격은 주당 $9.77입니다(2025년 11월 3일의 종가). 옵션은 4년에 걸쳐 취득되며: 1년 차에 25%의 취득 후, 이후 36개월 동안 매월 취득되며, 지속적인 근무 조건과 주식매수선택권 계약 및 계획에 따라 관리됩니다. 위원회는 Nasdaq Listing Rule 5635(c)(4)에 따라 유도(inducement)로서 보상을 승인했습니다.
Kura Oncology (Nasdaq : KURA) a annoncé que le 3 novembre 2025, son Comité de rémunération a accordé des options d’achat d’actions non statutaires pour inducement à un nouvel employé non cadre dans le cadre du plan 2023 Inducement Option Plan, tel que modifié.
L’octroi porte sur un total de 21 750 options avec un prix d’exercice de 9,77 $ par action (prix de clôture au 3 novembre 2025). Les options se vestent sur quatre ans : 25 % au bout d’un an, puis mensuellement au cours des 36 mois suivants, sous réserve de la poursuite du service, et sont régies par le plan et par un accord d’options sur actions. Le comité a approuvé l’attribution comme inducement conformément à la Nasdaq Listing Rule 5635(c)(4).
Kura Oncology (Nasdaq: KURA) gab bekannt, dass am 3. November 2025 sein Vergütungsausschuss induzierte, nicht statutarische Aktienoptionsrechte für einen neuen nicht leitenden Mitarbeiter gemäß dem 2023 Inducement Option Plan, wie geändert, gewährt hat.
Die Gewährung beläuft sich auf insgesamt 21.750 Optionen mit einem Ausübungspreis von 9,77 $ pro Aktie (Schlusskurs am 3. November 2025). Optionen werden über vier Jahre vesten: 25% nach einem Jahr, dann monatlich über die folgenden 36 Monate, vorbehaltlich fortgesetzter Tätigkeit, und unterliegen dem Plan und einer Aktienoptionsvereinbarung. Der Ausschuss genehmigte die Zuteilung als Inducement gemäß der Nasdaq Listing Rule 5635(c)(4).
كورا أونكولوجي (ناسداك: KURA) أعلنت أنه في 3 نوفمبر 2025 منح لجنة التعويض ح warrants inducement nonstatutory stock options إلى موظف جديد غير تنفيذي بموجب خطة خيارات التحفيز لعام 2023، كما تم تعديلها.
الممنوح مجموع 21,750 خياراً مع سعر ممارسة قدره 9.77 دولارات للسهم (سعر الإغلاق في 3 نوفمبر 2025). تُحقَق الخيارات خلال أربع سنوات: 25% بعد مرور عام واحد ثم شهرياً خلال الـ 36 شهراً التالية، رهناً بالاستمرار في الخدمة، وتخضع للخطة واتفاقية خيار الأسهم. وافق اللجنة على المنحة كتحفيز وفقاً لـ قاعدة إدراج ناسداك 5635(c)(4).
- None.
- None.
SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on November 3, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 21,750 shares of common stock to a new non-executive employee under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employee’s employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price equal to
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias, and continues to pioneer advancements in both menin inhibition and farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Contacts
Investors and media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
FAQ
What did Kura Oncology announce on November 7, 2025 regarding inducement grants (KURA)?
What is the exercise price and vesting schedule for the KURA inducement options?
How does the KURA inducement grant comply with Nasdaq rules?
Under which plan were the KURA inducement options granted?
Will the KURA inducement options immediately dilute existing shareholders?
